Paper41246331
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.
Aiello A and 22 others. Front Immunol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. Papers, record 41246331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41246331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Th1 Cells | Major topic |
| Multiple Sclerosis | Major topic |
| SARS-CoV-2 | Major topic |
| COVID-19 Vaccines | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Adult | |
| Cytokines | |
| Prospective Studies | |
| Immunosuppressive Agents | |
| Spike Glycoprotein, Coronavirus | |
| Fingolimod Hydrochloride | |
| Breakthrough Infections |
Source PubMed
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36367013 | Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. | Euro Surveill | 2022 | https://conductscience.org/library/papers/36367013 | PubMed |
| 2 | 34274038 | Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. | Lancet | 2021 | https://conductscience.org/library/papers/34274038 | PubMed |
| 3 | 34522051 | Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. | Nat Med | 2021 | https://conductscience.org/library/papers/34522051 | PubMed |
| 4 | 35526306 | Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. | EBioMedicine | 2022 | https://conductscience.org/library/papers/35526306 | PubMed |
| 5 | 22987802 | Macrophages induce differentiation of plasma cells through CXCL10/IP-10. | J Exp Med | 2012 | https://conductscience.org/library/papers/22987802 | PubMed |
| 6 | 38896777 | Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection. | Cell Rep | 2024 | https://conductscience.org/library/papers/38896777 | PubMed |
| 7 | 40086617 | Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: Utilizing host and pathogen biomarkers to enhance the tuberculosis elimination strategies. | Int J Infect Dis | 2025 | https://conductscience.org/library/papers/40086617 | PubMed |
| 8 | 35305296 | Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. | Lancet | 2022 | https://conductscience.org/library/papers/35305296 | PubMed |
| 9 | 36628884 | Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. | Mult Scler Relat Disord | 2023 | https://conductscience.org/library/papers/36628884 | PubMed |
| 10 | 40137720 | Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. | Pathogens | 2025 | https://conductscience.org/library/papers/40137720 | PubMed |
| 11 | 36037755 | Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies. | Mult Scler Relat Disord | 2022 | https://conductscience.org/library/papers/36037755 | PubMed |
| 12 | 35632451 | COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/35632451 | PubMed |
| 13 | 34648302 | mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. | Science | 2021 | https://conductscience.org/library/papers/34648302 | PubMed |
| 14 | 36522154 | Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. | J Neurol Neurosurg Psychiatry | 2023 | https://conductscience.org/library/papers/36522154 | PubMed |
| 15 | 36999398 | Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. | Clin Chem Lab Med | 2023 | https://conductscience.org/library/papers/36999398 | PubMed |
| 16 | 38932415 | SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/38932415 | PubMed |
| 17 | 39204049 | Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/39204049 | PubMed |
| 18 | 35235002 | Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. | J Neurol | 2022 | https://conductscience.org/library/papers/35235002 | PubMed |
| 19 | 39612915 | Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis. | Immunity | 2024 | https://conductscience.org/library/papers/39612915 | PubMed |
| 20 | 24655300 | Chemokines and chemokine receptors: positioning cells for host defense and immunity. | Annu Rev Immunol | 2014 | https://conductscience.org/library/papers/24655300 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCL10 | 3627 | PubTator's text mining | https://conductscience.org/library/genes/3627 | NCBI Gene |
| IFNB1 | 3456 | PubTator's text mining | https://conductscience.org/library/genes/3456 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41246331
GET https://conductscience.org/api/papers/v1/41246331/authors?page=2